BioWorld

Jan. 17, 2002

Inspire Comes Up Short In Phase III Study; Stock Falls 73 Percent

Inspire Pharmaceuticals Inc. said it’s not likely that the first Phase III trial of its lead product for dry eye will reach its endpoints. The negative news sent Inspire’s stock tumbling 73 percent. Read More

Immunex’s Enbrel Continues Growth, Receives 4th Approval

Merck Conducting Human Safety Trials Of Anti-HIV T-Lymphocyte Killers; No Antibodies Need Apply

Zonagen Opts To Move Forward Rather Than Explore Alternatives

Other News To Note

Correction/Clarification

La Jolla Raises $51.6M Privately To Fund Late-Stage Clinical Trials

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026